Upregulation of FUT1 has been reported to confer HCC cells with sorafenib resistance, and pharmacological inhibition of α1,2-fucosylation by 2-deoxy-D-galactose (2DGal) enhanced the therapeutic efficacy of sorafenib [68]. This evidence concerns the gene FUT1 and hepatocellular carcinoma.